
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Foodborne Pathog Dis</journal-id><journal-id journal-id-type="iso-abbrev">Foodborne Pathog. Dis</journal-id><journal-id journal-id-type="publisher-id">fpd</journal-id><journal-title-group><journal-title>Foodborne Pathogens and Disease</journal-title></journal-title-group><issn pub-type="ppub">1535-3141</issn><issn pub-type="epub">1556-7125</issn><publisher><publisher-name>Mary Ann Liebert, Inc.</publisher-name><publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26110358</article-id><article-id pub-id-type="pmc">4556337</article-id><article-id pub-id-type="publisher-id">10.1089/fpd.2015.1999</article-id><article-id pub-id-type="doi">10.1089/fpd.2015.1999</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Yet Another Flawed &#x0201c;Placebo Controlled&#x0201d; Study in Crohn's Disease?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Greenstein</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cameron</surname><given-names>D. William</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Sheldon T.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3,</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Surgery, <institution>James J. Peters Veterans Affairs Medical Center</institution>, Bronx, New York.</aff><aff id="aff2"><label><sup>2</sup></label>Department of Medicine, <institution>Ottawa Hospital Research Institute</institution>, Ottawa, Ontario, <country>Canada</country>.</aff><aff id="aff3"><label><sup>3</sup></label>Division of Infections Diseases, <institution>James J. Peters Veterans Affairs Medical Center</institution>, Bronx, New York.</aff><aff id="aff4"><label><sup>4</sup></label><institution>Inchan School of Medicine at Mount Sinai</institution>, New York, New York.</aff></contrib-group><author-notes><corresp><addr-line>Address correspondence to:</addr-line><addr-line><italic>Robert J. Greenstein, MD, FACS, FRCS (Eng)</italic></addr-line><addr-line><italic>Laboratory of Molecular Surgical Research</italic></addr-line><addr-line><italic>Research Block 4F-05</italic></addr-line><institution><italic>James J. Peters Veterans Affairs Medical Center</italic></institution><addr-line><italic>130 West Kingsbridge Road</italic></addr-line><addr-line><italic>Bronx, NY 10468</italic></addr-line><italic>E-mail:</italic><email xlink:href="mailto:Greenstein.Robert@gmail.com">Greenstein.Robert@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>9</month><year>2015</year><!--string-date: September 2015--></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>9</month><year>2015</year><!--string-date: September 2015--></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. --><volume>12</volume><issue>9</issue><fpage>812</fpage><lpage>812</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015; Published by Mary Ann Liebert, Inc.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This Open Access article is distributed under the terms of the Creative Commons License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="fpd.2015.1999.pdf"/><counts><ref-count count="5"/><page-count count="1"/></counts></article-meta></front><body><p>Dear Editor:</p><p>Accumulating data suggest that some variants of Crohn's disease (CD) may be consequent to a <italic>Mycobacterium avium</italic> subspecies <italic>paratuberculosis</italic> (MAP) infection. Opportunely, a prospective study (Kalfus, <xref rid="B3" ref-type="bibr">2013</xref>) is addressing the therapeutic role of appropriate antimycobacterial antimicrobials in CD. Potential inflammatory bowel disease (IBD) benefits may include identification of a mycobacterial etiology, improvement on current therapies, and possibly prevention.</p><p>MAP is inhibited by agents that the scientific community categorizes as anti-inflammatory (Greenstein <italic>et al.,</italic>
<xref rid="B2" ref-type="bibr">2007</xref>) and immune-modulators. (Krishnan <italic>et al.,</italic>
<xref rid="B4" ref-type="bibr">2009</xref>) A much-cited 2007 &#x0201c;placebo controlled&#x0201d; trial of anti-MAP antibiotics concluded that there was &#x0201c;no significant role for MAP in the pathogenesis of CD&#x0201d; (Selby <italic>et al.,</italic>
<xref rid="B5" ref-type="bibr">2007</xref>). Subsequent correspondence dismissed the possible corrupting influence of unanticipated &#x0201c;immune-modulator&#x0201d; anti-MAP inhibition as being &#x0201c;not consistent&#x0201d; with prevailing dogma. This was despite the editorial accompanying the 2007 study emphasizing significant improvement associated with concomitant use of &#x0201c;immune-modulators&#x0201d; (Selby <italic>et al.,</italic>
<xref rid="B5" ref-type="bibr">2007</xref>).</p><p>Disconcertingly, the inclusion criteria in the ongoing study (Kalfus, <xref rid="B3" ref-type="bibr">2013</xref>) are essentially identical to the prior &#x0201c;placebo&#x0201d;-controlled study (Selby <italic>et al.,</italic>
<xref rid="B5" ref-type="bibr">2007</xref>). Both ignore MAP inhibition by &#x0201c;anti-inflammatory&#x0201d; (Greenstein <italic>et al.,</italic>
<xref rid="B2" ref-type="bibr">2007</xref>) and &#x0201c;immune-modulators.&#x0201d; (Krishnan <italic>et al.,</italic>
<xref rid="B4" ref-type="bibr">2009</xref>) The 2007 study (Selby <italic>et al.,</italic>
<xref rid="B5" ref-type="bibr">2007</xref>) was designed before relevant MAP inhibition data (Greenstein <italic>et al.,</italic>
<xref rid="B2" ref-type="bibr">2007</xref>; Krishnan <italic>et al.,</italic>
<xref rid="B4" ref-type="bibr">2009</xref>) were published. The designers of the study now recruiting (Kalfus, <xref rid="B3" ref-type="bibr">2013</xref>) should explain why they ignore unrefuted published data that render their &#x0201c;placebo-controlled&#x0201d; study as flawed as previously (Selby <italic>et al.,</italic>
<xref rid="B5" ref-type="bibr">2007</xref>).</p><p>We suggest that calling the study now recruiting (Kalfus, <xref rid="B3" ref-type="bibr">2013</xref>) &#x0201c;placebo-controlled&#x0201d; is unscientific (Greenstein <italic>et al.,</italic>
<xref rid="B1" ref-type="bibr">2014</xref>). Multiple medications that inhibit infectious agents (Greenstein <italic>et al.,</italic>
<xref rid="B1" ref-type="bibr">2014</xref>) are permitted in both the &#x0201c;placebo&#x0201d; as well as treated groups. (Greenstein <italic>et al.,</italic>
<xref rid="B1" ref-type="bibr">2014</xref>). Previously, we have suggested that &#x0201c;add-on studies&#x0201d; is scientifically more accurate than &#x0201c;placebo-controlled&#x0201d; (Greenstein <italic>et al.,</italic>
<xref rid="B1" ref-type="bibr">2014</xref>).</p><p>A consistently flawed study design may yet again be misinterpreted as showing no added efficacy of anti-MAP agents in CD. Consequently, the potential identification of the etiology of IBD as being due to the zoonosis of MAP may irrevocably be lost.</p></body><back><ref-list content-type="parsed"><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenstein</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Cameron</surname><given-names>DW</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>ST</given-names></name></person-group>
<article-title>&#x0201c;Add-on&#x0201d; is scientifically more accurate than &#x0201c;placebo control&#x0201d; in multiple inflammatory bowel disease (IBD) trials</article-title>. <source>J Crohns Colitis</source>
<year>2014</year>;<volume>8</volume>:<fpage>1334</fpage>&#x02013;<lpage>1335</lpage><pub-id pub-id-type="pmid">24768214</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenstein</surname><given-names>RJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Su</surname><given-names>L</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Shahidi</surname><given-names>A</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Brown</surname><given-names>ST</given-names></name></person-group>
<article-title>On the action of 5-amino-salicylic acid and sulfapyridine on <italic>M. avium</italic> including subspecies <italic>paratuberculosis</italic></article-title>. <source>PLoS One</source>
<year>2007</year>;<volume>2</volume>:<fpage>e516</fpage><pub-id pub-id-type="pmid">17565369</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kalfus</surname><given-names>I</given-names></name></person-group>
<source>A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn's Disease</source>, volume 2015. <publisher-name>U.S. National Institutes of Health</publisher-name>, <year>2013</year> Available at: <uri xlink:type="simple" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</uri>, accessed <date-in-citation><month>6</month><day>17</day>, <year>2015</year></date-in-citation></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>MY</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Manning</surname><given-names>EJ</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Collins</surname><given-names>MT</given-names></name></person-group>
<article-title>Effects of interactions of antibacterial drugs with each other and with 6-mercaptopurine on in vitro growth of <italic>Mycobacterium avium</italic> subspecies <italic>paratuberculosis</italic></article-title>. <source>J Antimicrob Chemother</source>
<year>2009</year>;<volume>64</volume>:<fpage>1018</fpage>&#x02013;<lpage>1023</lpage><pub-id pub-id-type="pmid">19759042</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selby</surname><given-names>W</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Pavli</surname><given-names>P</given-names></name></person-group>, <person-group person-group-type="author"><name><surname>Crotty</surname><given-names>B</given-names></name>, <etal><italic>et al.</italic></etal></person-group>
<article-title>Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease</article-title>. <source>Gastroenterology</source>
<year>2007</year>;<volume>132</volume>:<fpage>2313</fpage>&#x02013;<lpage>2319</lpage><pub-id pub-id-type="pmid">17570206</pub-id></mixed-citation></ref></ref-list></back></article>